Journal: The Journal of Headache and Pain

Article Title: Progesterone distribution in the trigeminal system and its role to modulate sensory neurotransmission: influence of sex

doi: 10.1186/s10194-023-01687-x

Figure Lengend Snippet: Effect of progesterone on CGRP release from dura mater and TG in male and female rats. Displayed in the four panels are the CGRP release profiles for male dura mater ( A ), male TG ( B ), female dura mater ( C ), and female TG ( D ). In each instance, the tissues were exposed to 10 µM progesterone or vehicle, and the subsequent CGRP release is illustrated. The data, represented as mean ± SEM, ( n = 5), are expressed as a percentage of the vehicle control, indicating no significant impact of progesterone on CGRP release across all conditions

Article Snippet: The CGRP release from the TG samples and the cranium halves were initially assessed under basal conditions, followed by an evaluation under the influence of progesterone (Cat. No. 2835, Biotechne, Ireland) dissolved in DMSO (Sigma-Aldrich, Germany) after a 15-min incubation to test for potential progesterone-induced release.

Techniques:

Journal: The Journal of Headache and Pain

Article Title: Progesterone distribution in the trigeminal system and its role to modulate sensory neurotransmission: influence of sex

doi: 10.1186/s10194-023-01687-x

Figure Lengend Snippet: Examination of progesterone's modulation on capsaicin induced CGRP release from rat dura mater and TG. The impact of progesterone on capsaicin induced CGRP release in both male and female rat tissues. The panels illustrate CGRP release following pre-treatment with 10 µM progesterone/vehicle and subsequent addition of 100 nM capsaicin in male dura mater ( A ), male TG ( B ), female dura mater ( C ), and female TG ( D ). In the male dura mater, there is a trend towards increased CGRP release, whereas a significant reduction is observed in the male TG. No substantial changes are noted in female tissues. Data are presented as mean ± SEM ( n = 5) and are displayed as a percentage of the vehicle control. Statistical significance was determined using Student's t-test, with * = P < 0.05 indicating a significant difference

Article Snippet: The CGRP release from the TG samples and the cranium halves were initially assessed under basal conditions, followed by an evaluation under the influence of progesterone (Cat. No. 2835, Biotechne, Ireland) dissolved in DMSO (Sigma-Aldrich, Germany) after a 15-min incubation to test for potential progesterone-induced release.

Techniques:

Journal: Experimental Biology and Medicine

Article Title: Ultrasonographic assessment of skeletal muscles after experimentally induced neurogenic inflammation (facet injury) in rats

doi: 10.1177/15353702221119802

Figure Lengend Snippet: Western blotting results of the relative expression of inflammatory regulators determined in left biceps brachii and rectus femoris homogenates collected post-mortem 21 days after experimental procedures in sham-operated and experimental surgery (lumbar L4–L6 facet injury) rats.

Article Snippet: The primary antibodies used were as follows: anti-substance P (SP) antibody at 1:500 (orb215527), anti-calcitonin-gene-related peptide (CGRP) 1:250 (orb182870), and anti-PAR2 antibody at 1:500 (orb385619); Biorbyt Ltd., San Francisco, CA, USA; anti-proline-directed kinases (ERK1/2) antibody at 1:1000 (#9102); and anti-Ca2 + /calmodulin-dependent protein kinase II (CaMKII) antibody at 1:1000 (#4436); Cell Signaling Technology, Denver, MA, USA.

Techniques: Western Blot, Expressing

Journal: Nature Communications

Article Title: G z ESTY as an optimized cell-based assay for initial steps in GPCR deorphanization

doi: 10.1038/s41467-025-59850-8

Figure Lengend Snippet: A Real-time analysis of ligand-mediated activation of a battery of G i/o/z -PCRs (red) and G s -PCR (green) in cells co-transfected with indicated receptors and the 3-in-one G z ESTY plasmid in the presence of 50 µM IBMX. Cells transfected only with the 3-in-one plasmid served as control (white). The following agonists were applied at 4 min: 10 µM dopamine (D2R, D1R), 100 µM clonidine (ADRA2A, ADRA2B, ADRA2C), 10 µM GABA (GABABR), 10 µM DAMGO (MOR), 1 µM SNC-80 (DOR), 10 µM salvinorin A (KOR), 10 µM human galanin (1–30) (GAL1R), 100 µM serotonin (5-HT1B), 10 µM human neuropeptide Y (13–36) (NPYR1), 10 µM lysophosphatidic acid (LPAR2), 10 µM 2-arachidonoyl glycerol (CB1R, CB2R), 10 µM N-formyl-met-leu-phe (FPR1), 1 mM isobutyric acid (FFAR3), 10 µM somatostatin 14 (SSTR1), 10 µM neuropeptide FF (NPFFR1), 10 µM SEW2871 (S1PR1), 10 µM histamine (HRH3), 10 µM quinpirole (D3R), 10 µM TFLLR (PAR1), 10 µM SLIGKV (PAR2), 10 µM MK-6892 (HCA2R), 1 µM teriparatide PTH (PTH1R), 10 µM AB-MECA (ADORA2B), 10 µM NDP-α-MSH (MC4R), and 10 µM CGRP (CLR). Data are shown as means ± SEM; N = 5 independent transfections. B GPCRs that couple to G s and/or G i/o/z and can potentially be detected by GZESTY are highlighted and include 213 out of 249 total ligand-activated GPCRs (86%) (adapted from GPRCdb.org). C Quantification of agonist-induced activity for 24 G i/o/z -coupled GPCRs. On the right, the response to agonist of the last seven GPCRs is also reported with a different scale. Data are shown as means ± SEM of the fold change obtained; N = 5 independent transfections.

Article Snippet: The following chemicals were purchased: clonidine (Tocris), dopamine (Tocris), GABA (Tocris), serotonin (Tocris), 1-oleoyl lysophosphatidic acid (Tocris), DAMGO (MedChemExpress), TFLLR (MedChemExpress), human PAR-2 (1-6, SLIGKV) (MedChemExpress), human galanin (1–30) (MedChemExpress), IBMX (MedChemExpress), SEW2871 (MedChemExpress), somatostatin-14 (Cpc Scientific), human neuropeptide Y (13-36) (Cpc Scientific), neuropeptide FF (Thermo Scientific Chemicals), MK-6892 (MedChemExpress), 2-arachidonoyl glycerol (Cayman Chemicals), N-Formyl-Met-Leu-Phe (R&D systems), SNC80 (Adipogen), isobutyric acid (TCI chemicals), salvinorin A (ChromaDex Inc.), morphine (Mallinckrodt Chemical Company), human β-endorphin (Sigma-Aldrich), teriparatide (MedChemExpress), NDP-α-MSH (Phoenix Pharmaceuticals), AB-MECA (MedChemExpress), quinpirole (Tocris), calcitonin gene-related peptide (CGRP) (AnaSpec), AM-251 (Tocris; #1117), carbachol (Tocris; #2810), L-741626 (Tocris; #1003), RS-79948 (Tocris; #0987), saclofen (MCE; #HY-100813), and naloxone (Tocris; #0599).

Techniques: Activation Assay, Battery, Transfection, Plasmid Preparation, Control, Activity Assay